These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 32835256)

  • 41. Fever Patterns, Cytokine Profiles, and Outcomes in COVID-19.
    Ng DHL; Choy CY; Chan YH; Young BE; Fong SW; Ng LFP; Renia L; Lye DC; Chia PY;
    Open Forum Infect Dis; 2020 Sep; 7(9):ofaa375. PubMed ID: 32999893
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Alpha-1 adrenergic receptor antagonists to prevent hyperinflammation and death from lower respiratory tract infection.
    Koenecke A; Powell M; Xiong R; Shen Z; Fischer N; Huq S; Khalafallah AM; Trevisan M; Sparen P; Carrero JJ; Nishimura A; Caffo B; Stuart EA; Bai R; Staedtke V; Thomas DL; Papadopoulos N; Kinzler KW; Vogelstein B; Zhou S; Bettegowda C; Konig MF; Mensh B; Vogelstein JT; Athey S
    ArXiv; 2021 Aug; ():. PubMed ID: 32550250
    [TBL] [Abstract][Full Text] [Related]  

  • 43. GM-CSF Neutralization With Lenzilumab in Severe COVID-19 Pneumonia: A Case-Cohort Study.
    Temesgen Z; Assi M; Shweta FNU; Vergidis P; Rizza SA; Bauer PR; Pickering BW; Razonable RR; Libertin CR; Burger CD; Orenstein R; Vargas HE; Palraj R; Dababneh AS; Chappell G; Chappell D; Ahmed O; Sakemura R; Durrant C; Kenderian SS; Badley AD
    Mayo Clin Proc; 2020 Nov; 95(11):2382-2394. PubMed ID: 33153629
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of Recombinant Human Granulocyte Colony-Stimulating Factor for Patients With Coronavirus Disease 2019 (COVID-19) and Lymphopenia: A Randomized Clinical Trial.
    Cheng LL; Guan WJ; Duan CY; Zhang NF; Lei CL; Hu Y; Chen AL; Li SY; Zhuo C; Deng XL; Cheng FJ; Gao Y; Zhang JH; Xie JX; Peng H; Li YX; Wu XX; Liu W; Peng H; Wang J; Xiao GM; Chen PY; Wang CY; Yang ZF; Zhao JC; Zhong NS
    JAMA Intern Med; 2021 Jan; 181(1):71-78. PubMed ID: 32910179
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes.
    Leisman DE; Ronner L; Pinotti R; Taylor MD; Sinha P; Calfee CS; Hirayama AV; Mastroiani F; Turtle CJ; Harhay MO; Legrand M; Deutschman CS
    Lancet Respir Med; 2020 Dec; 8(12):1233-1244. PubMed ID: 33075298
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A whole blood test to measure SARS-CoV-2-specific response in COVID-19 patients.
    Petrone L; Petruccioli E; Vanini V; Cuzzi G; Najafi Fard S; Alonzi T; Castilletti C; Palmieri F; Gualano G; Vittozzi P; Nicastri E; Lepore L; Antinori A; Vergori A; Caccamo N; Cantini F; Girardi E; Ippolito G; Grifoni A; Goletti D
    Clin Microbiol Infect; 2021 Feb; 27(2):286.e7-286.e13. PubMed ID: 33045370
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy of Tocilizumab in Patients Hospitalized with Covid-19.
    Stone JH; Frigault MJ; Serling-Boyd NJ; Fernandes AD; Harvey L; Foulkes AS; Horick NK; Healy BC; Shah R; Bensaci AM; Woolley AE; Nikiforow S; Lin N; Sagar M; Schrager H; Huckins DS; Axelrod M; Pincus MD; Fleisher J; Sacks CA; Dougan M; North CM; Halvorsen YD; Thurber TK; Dagher Z; Scherer A; Wallwork RS; Kim AY; Schoenfeld S; Sen P; Neilan TG; Perugino CA; Unizony SH; Collier DS; Matza MA; Yinh JM; Bowman KA; Meyerowitz E; Zafar A; Drobni ZD; Bolster MB; Kohler M; D'Silva KM; Dau J; Lockwood MM; Cubbison C; Weber BN; Mansour MK;
    N Engl J Med; 2020 Dec; 383(24):2333-2344. PubMed ID: 33085857
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial.
    Hermine O; Mariette X; Tharaux PL; Resche-Rigon M; Porcher R; Ravaud P;
    JAMA Intern Med; 2021 Jan; 181(1):32-40. PubMed ID: 33080017
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Tocilizumab in patients with severe COVID-19: a retrospective cohort study.
    Guaraldi G; Meschiari M; Cozzi-Lepri A; Milic J; Tonelli R; Menozzi M; Franceschini E; Cuomo G; Orlando G; Borghi V; Santoro A; Di Gaetano M; Puzzolante C; Carli F; Bedini A; Corradi L; Fantini R; Castaniere I; Tabbì L; Girardis M; Tedeschi S; Giannella M; Bartoletti M; Pascale R; Dolci G; Brugioni L; Pietrangelo A; Cossarizza A; Pea F; Clini E; Salvarani C; Massari M; Viale PL; Mussini C
    Lancet Rheumatol; 2020 Aug; 2(8):e474-e484. PubMed ID: 32835257
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial.
    Vlaar APJ; de Bruin S; Busch M; Timmermans SAMEG; van Zeggeren IE; Koning R; Ter Horst L; Bulle EB; van Baarle FEHP; van de Poll MCG; Kemper EM; van der Horst ICC; Schultz MJ; Horn J; Paulus F; Bos LD; Wiersinga WJ; Witzenrath M; Rueckinger S; Pilz K; Brouwer MC; Guo RF; Heunks L; van Paassen P; Riedemann NC; van de Beek D
    Lancet Rheumatol; 2020 Dec; 2(12):e764-e773. PubMed ID: 33015643
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia.
    Salama C; Han J; Yau L; Reiss WG; Kramer B; Neidhart JD; Criner GJ; Kaplan-Lewis E; Baden R; Pandit L; Cameron ML; Garcia-Diaz J; Chávez V; Mekebeb-Reuter M; Lima de Menezes F; Shah R; González-Lara MF; Assman B; Freedman J; Mohan SV
    N Engl J Med; 2021 Jan; 384(1):20-30. PubMed ID: 33332779
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Mavrilimumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation (MASH-COVID): an investigator initiated, multicentre, double-blind, randomised, placebo-controlled trial.
    Cremer PC; Abbate A; Hudock K; McWilliams C; Mehta J; Chang SY; Sheng CC; Van Tassell B; Bonaventura A; Vecchié A; Carey B; Wang Q; Wolski KE; Rajendram P; Duggal A; Wang TS; Paolini JF; Trapnell BC;
    Lancet Rheumatol; 2021 Jun; 3(6):e410-e418. PubMed ID: 33754144
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Uncontrolled Innate and Impaired Adaptive Immune Responses in Patients with COVID-19 Acute Respiratory Distress Syndrome.
    Hue S; Beldi-Ferchiou A; Bendib I; Surenaud M; Fourati S; Frapard T; Rivoal S; Razazi K; Carteaux G; Delfau-Larue MH; Mekontso-Dessap A; Audureau E; de Prost N
    Am J Respir Crit Care Med; 2020 Dec; 202(11):1509-1519. PubMed ID: 32866033
    [No Abstract]   [Full Text] [Related]  

  • 54. Is G-CSF Dangerous in COVID-19: Why Not Use GM-CSF?
    Lazarus HM; Gale RP
    Acta Haematol; 2021; 144(3):350-351. PubMed ID: 33161397
    [No Abstract]   [Full Text] [Related]  

  • 55. Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial.
    Salvarani C; Dolci G; Massari M; Merlo DF; Cavuto S; Savoldi L; Bruzzi P; Boni F; Braglia L; Turrà C; Ballerini PF; Sciascia R; Zammarchi L; Para O; Scotton PG; Inojosa WO; Ravagnani V; Salerno ND; Sainaghi PP; Brignone A; Codeluppi M; Teopompi E; Milesi M; Bertomoro P; Claudio N; Salio M; Falcone M; Cenderello G; Donghi L; Del Bono V; Colombelli PL; Angheben A; Passaro A; Secondo G; Pascale R; Piazza I; Facciolongo N; Costantini M;
    JAMA Intern Med; 2021 Jan; 181(1):24-31. PubMed ID: 33080005
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19.
    Gupta S; Wang W; Hayek SS; Chan L; Mathews KS; Melamed ML; Brenner SK; Leonberg-Yoo A; Schenck EJ; Radbel J; Reiser J; Bansal A; Srivastava A; Zhou Y; Finkel D; Green A; Mallappallil M; Faugno AJ; Zhang J; Velez JCQ; Shaefi S; Parikh CR; Charytan DM; Athavale AM; Friedman AN; Redfern RE; Short SAP; Correa S; Pokharel KK; Admon AJ; Donnelly JP; Gershengorn HB; Douin DJ; Semler MW; Hernán MA; Leaf DE;
    JAMA Intern Med; 2021 Jan; 181(1):41-51. PubMed ID: 33080002
    [TBL] [Abstract][Full Text] [Related]  

  • 57. SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19.
    Chen P; Nirula A; Heller B; Gottlieb RL; Boscia J; Morris J; Huhn G; Cardona J; Mocherla B; Stosor V; Shawa I; Adams AC; Van Naarden J; Custer KL; Shen L; Durante M; Oakley G; Schade AE; Sabo J; Patel DR; Klekotka P; Skovronsky DM;
    N Engl J Med; 2021 Jan; 384(3):229-237. PubMed ID: 33113295
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Granulocyte colony-stimulating factors (G-CSF) and Covid-19: a double-edged sword?
    Tralongo AC; Danova M
    Infez Med; 2020 Sep; 28(3):459-460. PubMed ID: 32920586
    [TBL] [Abstract][Full Text] [Related]  

  • 59. How to Use Prophylactic G-CSF in the Time of COVID-19.
    Lasagna A; Zuccaro V; Ferraris E; Rizzo G; Tancredi RJ; Pedrazzoli P
    JCO Oncol Pract; 2020 Nov; 16(11):771-772. PubMed ID: 32877272
    [No Abstract]   [Full Text] [Related]  

  • 60. Immune Stimulation With Recombinant Human Granulocyte Colony-Stimulating Factor for Coronavirus Disease 2019 (COVID-19)-Beware of Blind Spots.
    Meyer NJ; Lindell RB; Wherry EJ
    JAMA Intern Med; 2021 Jan; 181(1):78-80. PubMed ID: 32910155
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.